(Q46304977)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

title

Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

P C Shaw

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

language of work or name

English

0 references

publication date

1 January 1999

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

page(s)

355-368

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

Minireview: trichosanthin--a protein with multiple pharmacological properties

10 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Trichosanthin treatment of HIV-induced immune dysregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

A phase II study of effect of addition of trichosanthin to zidovudine in patients with HIV disease and failing antiretroviral agents

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

A phase I/II study of trichosanthin treatment of HIV disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Safety, activity, and pharmacokinetics of GLQ223 in patients with AIDS and AIDS-related complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Renal reabsorption of trichosanthin and the effect on GFR

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Neurological reactions in HIV-infected patients treated with trichosanthin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Biomedical and biotechnological applications of PEG- and PM-modified proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

A preliminary study on the evaluation of asparaginase. Polyethylene glycol conjugate against canine malignant lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Site-directed pegylation of recombinant interleukin-2 at its glycosylation site

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Polyethylene glycol (PEG) modification of granulocyte-macrophage colony stimulating factor (GM-CSF) enhances neutrophil priming activity but not colony stimulating activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Long-acting growth hormones produced by conjugation with polyethylene glycol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

High level synthesis of biologically active recombinant trichosanthin in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Increasing the plasma half-life of trichosanthin by coupling to dextran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

An efficient mRNA-dependent translation system from reticulocyte lysates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

The biological activities of trichosanthin after coupling to dextran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

PCA Reactions with Mouse Antibodies in Mice and Rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Polyethylene glycol reactive antibodies in man: titer distribution in allergic patients treated with monomethoxy polyethylene glycol modified allergens or placebo, and in healthy blood donors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

Clinical trials with Dismutec (pegorgotein; polyethylene glycol-conjugated superoxide dismutase; PEG-SOD) in the treatment of severe closed head injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0024-3205%2899%2900257-X

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0024-3205(99)00257-X

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json

10 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10421422%20AND%20SRC:MED&resulttype=core&format=json